secwatch.observer — SEC 8-K summary
======================================

Issuer:     Raphael Pharmaceutical Inc. (RAPH)
CIK:        0001415397
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001213900-25-073909
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Raphael Pharmaceutical ready to launch RaphaWell RA supplement in US after clinical trial
--------------------------------------------------------------------------------

- RaphaWell is a 100% natural, plant-based dietary supplement for rheumatoid arthritis symptom management.
- Completed proof-of-concept clinical trial under IRB approval; pain levels reduced from 75% negative to 50% at week 8.
- Morning stiffness improved from 75% participants at baseline to 41.67% at week 8.
- Company intends to engage a US manufacturer to scale production; product to be sold as standalone supplement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1415397/000121390025073909/0001213900-25-073909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1415397/000121390025073909/ea0252574-8k_raphael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-073909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer